Siplizumab [288392-69-8]

TargetMol Chemicals

Siplizumab

9

288392-69-8

Antibody

Research Use Only

Siplizumab

SDS-PAGE:95% SEC-HPLC:99.99%

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.

3 years

-20°C

12352203